These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18814092

  • 1. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
    Stähler G.
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
    [Abstract] [Full Text] [Related]

  • 2. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D, Humbert M.
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract] [Full Text] [Related]

  • 3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [Abstract] [Full Text] [Related]

  • 5. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL, Michelakis ED.
    Curr Opin Cardiol; 2006 Jul 08; 21(4):385-92. PubMed ID: 16755209
    [Abstract] [Full Text] [Related]

  • 6. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
    Don GW, Joseph F, Celermajer DS, Corte TJ.
    Intern Med J; 2012 Dec 08; 42(12):1351-4. PubMed ID: 23253000
    [Abstract] [Full Text] [Related]

  • 7. [Drug combination treatment for pulmonary arterial hypertension].
    Ghofrani HA, Hoeper MM.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S330-3. PubMed ID: 17139600
    [Abstract] [Full Text] [Related]

  • 8. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M.
    Rev Med Interne; 2007 Dec 08; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract] [Full Text] [Related]

  • 9. An evidence-based approach to the management of pulmonary arterial hypertension.
    Coyne TC.
    Curr Opin Cardiol; 2006 Sep 08; 21(5):526; author reply 526-7. PubMed ID: 16900019
    [No Abstract] [Full Text] [Related]

  • 10. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G, Mehta S.
    Appl Health Econ Health Policy; 2009 Sep 08; 7(1):43-59. PubMed ID: 19558194
    [Abstract] [Full Text] [Related]

  • 11. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
    Pitsiou GG, Chavouzis N, Nakou C, Boutou AK, Argyropoulou P, Stanopoulos I.
    J Heart Lung Transplant; 2009 Jun 08; 28(6):651-3. PubMed ID: 19481029
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.
    Can J Cardiol; 2013 Jun 08; 29(6):672-7. PubMed ID: 22819360
    [Abstract] [Full Text] [Related]

  • 13. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE.
    Arthritis Rheum; 2009 Feb 08; 60(2):569-77. PubMed ID: 19180517
    [Abstract] [Full Text] [Related]

  • 14. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M, Galiè N.
    J Am Coll Cardiol; 2009 Mar 03; 53(9):733-40. PubMed ID: 19245962
    [Abstract] [Full Text] [Related]

  • 15. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Mar 03; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 16. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J, Hoeper MM.
    Eur Respir J; 2008 Feb 03; 31(2):407-15. PubMed ID: 18238950
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA, Grimminger F.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [Abstract] [Full Text] [Related]

  • 18. Idiopathic pulmonary arterial hypertension.
    Souza R, Jardim C, Humbert M.
    Semin Respir Crit Care Med; 2013 Oct 08; 34(5):560-7. PubMed ID: 24037625
    [Abstract] [Full Text] [Related]

  • 19. The current treatment of pulmonary arterial hypertension: time to redefine success.
    Rich S.
    Chest; 2006 Oct 08; 130(4):1198-202. PubMed ID: 17035456
    [Abstract] [Full Text] [Related]

  • 20. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I, Otero-González I, Blanco-Aparicio M, Ferrer-Barba A, Medrano-López C.
    Rev Esp Cardiol; 2007 Apr 08; 60(4):366-72. PubMed ID: 17521545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.